Why the study?
Does intravenous disopyramide phosphate convert recurrent paroxysmal tachycardias to sinus rhythm?
Does intravenous disopyramide phosphate convert recurrent paroxysmal tachycardias to sinus rhythm?
Intravenous disopyramide phosphate is effective in converting various paroxysmal tachycardias to sinus rhythm but is associated with significant arrhythmogenic and hemodynamic side effects.
May support acute conversion in select paroxysmal tachycardias despite side effects; leaves open comparative safety and efficacy versus alternatives.
1 Reccurent paroxysmal atrial, atrioventricular and ventricular tachycardias in 50 patients without acute coronary insufficiency, heart failure or metabolic abnormlity were treated with disopyramide phosphate in a dose of 2 mg/kg body weight infused over 5 min. 2 Conversion to sinus rhythm within 10 min of the completed infusion occurred in 10 of 14 (71%) patients with paroxysmal 'lone' atrial fibrillation, 3 of 7 (43%) patients with paroxysmal atrial flutter, 6 of 9 (67%) patients with paroxysmal atrial tachycardia, 5 of 9 (56%) patients with paroxysmal atrioventricular tachycardia associated with the Wolff-Parkinson-White syndrome and 8 of 11 (73%) patients with paroxysmal ventricular tachycardia. 3 Side effects: significant systemic hypotension in 3, high grade AV block in 1, an increased ventricular response producing symptoms in 4, post conversion asystole in 1 land sinus bradycardia in 2. 4 The anti-arrhythmic effect and arrhythmogenic side effects may be related to both the direct membrane stabilizing effect and the anticholinergic effect of disopyramide.
No takes yet. Share an insight, caveat, or question.
Camm et al. (1979) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: